ClinicalTrials.gg
CompletedNCT05547451VACOVAJIUpdated Nov 19, 2026

SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

An observational study in SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis, sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nantes University Hospital · Observational

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
9
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.

Enrollment
19th of 21
9 · median 274
Started
2024
with 3 others
Observational
21 of 71
5 open now
Registered
59th of 71
by date

Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 19th largest by enrollment of the 21 observational ones that give a count, is one of 4 that started in 2024, is one of 21 observational ones, and was the 59th registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Arthritis, Juvenile with a site in France, or all of them as a file.
02

Study summary

Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.

03

Conditions studied

  • SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • SARS Cov2 vaccination
  • juvenile idiopathic arthritis
  • paediatric
  • safety
  • acceptance
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from 12 to 18 years old followed up from juvenile arthritis in 2021 and 2022 at Angers, Nantes and Rennes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from 12 to 18 years old, on January the 1st 2022
  • Patients followed up from juvenile arthritis
  • Patients followed up in 2021 and 2022

Exclusion criteria

Exclusion Criteria:

  • Patients under 12 years old.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
9 participants (actual)
Patient registry
No

Groups and cohorts

  • Trial population

    Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.

06

What researchers measure

Primary outcomes

  1. SARS Cov2 vaccination coverage of this population and factors influencing the realization of the vaccination.

    Percentage of patients vaccinated

    Time frame: From june 2021 to December 2022

Secondary outcomes

  1. Tolerance of the SARS-Cov2 vaccination

    Occurrence of any side-effects

    Time frame: From june 2021 to December 2022

  2. Effect of the SARS Cov2 vaccination on juvenile arthritis

    Occurrence of flare up of the illness, modification of treatment

    Time frame: From june 2021 to December 2022

  3. SARS-Cov 2 infection after vaccination

    Occurrence and severity of the infection

    Time frame: From june 2021 to December 2022

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2024 to primary completion in Sep 2024, 3 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jun 2025 → Sep 2024 and completion Jun 2025 → Sep 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 21, 2022
StartActual
Jun 9, 2024
Primary completionActual
Sep 30, 2024was Jun 2025
CompletionActual
Sep 30, 2024was Jun 2025
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Jun 30, 2025→Sep 30, 2024 (actual)
Nov 19, 2026
Study completion
Jun 30, 2025→Sep 30, 2024 (actual)
Nov 19, 2026
Enrollment
200 (estimated)→9 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2025→Sep 30, 2024 (now actual)
    Study completion Jun 30, 2025→Sep 30, 2024 (now actual)
    Enrollment 200 (estimated)→9 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05547451
Collaborators
University Hospital, Angers, Rennes University Hospital, Clinique de l'Anjou
Responsible party
Sponsor
First posted
Sep 21, 2022
Start date
Jun 9, 2024
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion